statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), an experienced and innovative biotechnology company committed to transforming peoples lives by silencing diseases through precision...

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Over the last three days, A.I.dvisor has detected that SLN's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line...

Silence Therapeutics (SLN, $21.93) Aroon Indicator entered an Uptrend on March 22, 2024.

Silence Therapeutics (SLN, $22.69) Aroon Indicator entered an Uptrend on March 21, 2024.

Silence Therapeutics (SLN, $22.91) Aroon Indicator entered an Uptrend on March 20, 2024.

Silence Therapeutics (SLN, $23.34) Aroon Indicator entered an Uptrend on March 19, 2024.

Silence Therapeutics (SLN, $24.04) Aroon Indicator entered an Uptrend on March 18, 2024.

Silence Therapeutics (SLN, $23) Aroon Indicator entered an Uptrend on March 15, 2024.

Silence Therapeutics (SLN, $23.85) Aroon Indicator entered an Uptrend on March 14, 2024.

Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.
read more...

These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Silence Therapeutics announces ALPACAR-360 met primary endpoint

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc - ADR

Volume	51,034.00
52-Wk High	$27.72
52-Wk Low	$4.60

SLN Silence Therapeutics Plc - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals